As such, this section will discuss how tumor-derived alterations in arginine, glutamine, and methionine metabolism contribute to anti-tumor immunity and how modifying the metabolism of these amino acids helps diminish resistance to anti-PD-1/PD-L1 therapy. This evidence concerns the gene PDCD1 and neoplasm.